Description

SS-31 (Elamipretide) Peptide Vials

SS-31 (Elamipretide)
CAS Number	1334953-95-5
Molar Mass	639.8 g/mol
Chemical Structure	C32H49N9O
IUPAC Name	D-Arg- dimethyl-Tyr-Lys-Phe-NH2

Introduction

SS-31, also known as Elamipretide, is a small peptide compound that belongs to a class known as mitochondria-targeted peptides. SS-31 has garnered attention for its potential therapeutic applications in various medical conditions, particularly those involving mitochondrial dysfunction and oxidative stress.

Key Characteristics

Mitochondria are cellular organelles responsible for producing energy in the form of ATP (adenosine triphosphate) through oxidative phosphorylation. They also play a crucial role in regulating cell death pathways and maintaining cellular homeostasis. Dysfunction of mitochondria can lead to various diseases and conditions, including neurodegenerative disorders, cardiovascular diseases, and metabolic disorders.

SS-31 potentially targets the inner mitochondrial membrane, where it interacts with cardiolipin, a phospholipid crucial for mitochondrial function. By binding to cardiolipin, SS-31 may help stabilize mitochondrial membranes, enhance ATP production, and reduce oxidative stress and cell death.

Research Applications

Research suggests that SS-31 may have therapeutic potential in several medical conditions, including heart failure, neurodegenerative diseases like Alzheimer’s and Parkinson’s, ischemia-reperfusion injury, and age-related decline in mitochondrial function.

Clinical trials investigating the efficacy and safety of SS-31 in various diseases are ongoing, reflecting the growing interest in mitochondria-targeted therapies as a novel approach to treating a range of medical conditions.

SS-31 and Cognitive Function

In experiments with mice, the introduction of LPS, a substance known to induce inflammation, led to various cognitive impairments, including mitochondrial dysfunction, oxidative stress, inflammation, neuronal cell death, and structural changes in brain cells. 

These deficits resulted in difficulties with learning and memory tasks in standard behavioral tests. However, treatment with Elamipretide significantly improved cognitive performance in these tests. Elamipretide protects against mitochondrial dysfunction and oxidative stress but positively influences brain signaling pathways associated with synaptic function and structure. 

These findings suggest that Elamipretide holds promise as a therapeutic intervention for conditions associated with cognitive impairment.

SS-31 and Sleep Deprivation

The findings of a recent study suggest promising implications for using SS-31 to mitigate the cognitive effects of sleep deprivation. By targeting mitochondrial dysfunction, inflammation, and synaptic dysfunction, SS-31 showed the potential to improve cognitive impairments induced by chronic sleep deprivation. 

These results highlight SS-31 as a candidate for further exploration in addressing cognitive deficits associated with sleep disturbances, potentially offering therapeutic benefits for individuals experiencing sleep deprivation-related cognitive impairment.

SS-31 Emerging Role in Pre-Clinical Studies

SS-31 has shown promising results in preclinical studies by enhancing mitochondrial function, which benefits various organ systems, such as skeletal muscles, eyes, brain, heart, and kidneys. 

Significantly, it has advanced into clinical trials for conditions including mitochondrial myopathy, autosomal genetic diseases, mitochondrial genetic diseases, heart failure, myocardial reperfusion injury, renal reperfusion injury, and age-related skeletal muscle issues.

Summary

SS-31, also known as Elamipretide, is a mitochondria-targeted peptide compound with potential therapeutic applications for mitochondrial dysfunction and oxidative stress conditions. In preclinical studies, it has demonstrated benefits across multiple organ systems. Ongoing clinical trials are exploring its efficacy and safety in various diseases, including heart failure, neurodegenerative disorders, and mitochondrial myopathy. 

 

Additionally, recent research suggests SS-31’s potential to improve cognitive impairments induced by conditions such as sleep deprivation, highlighting its promising role in addressing cognitive deficits associated with mitochondrial dysfunction.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the Institutional Animal Care and Use Committee (IACUC) directives, adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed to provide research-oriented insights. However, it is not a substitute for individual analysis and verification from credible sources before making any purchasing decisions.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Zhao W, Xu Z, Cao J, Fu Q, Wu Y, Zhang X, Long Y, Zhang X, Yang Y, Li Y, Mi W. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019 Nov 20;16(1):230. doi: 10.1186/s12974-019-1627-9. PMID: 31747905; PMCID: PMC6865061. [Read More]
2. Zhang YM, Wang YT, Wei RM, Li XY, Luo BL, Zhang JY, Zhang KX, Fang SK, Liu XC, Chen GH. Mitochondrial antioxidant Elamipretide improves learning and memory impairment induced by chronic sleep deprivation in mice. Brain Behav. 2024 May;14(5):e3508. doi: 10.1002/brb3.3508. PMID: 38688894; PMCID: PMC11061203. [Read More]

Xinrong Du, Qin Zeng, Yunchang Luo, Libing He, Yuhong Zhao, Ninjing Li, Changli Han, Guohui Zhang, Weixin Liu, Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction, Mitochondrion, Volume 75, 2024, 101846, ISSN 1567-7249, https://doi.org/10.1016/j.mito.2024.101846. [Read More]